Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart scan sub-study tests Drug's effect on sticky protein buildup

NCT ID NCT06073587

Ongoing Disease control Sponsor: Ionis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 28, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study is for people with a heart condition called ATTR-CM, where a protein called transthyretin builds up in the heart. It tests whether the drug eplontersen can reduce that buildup compared to a placebo. About 150 participants will have special heart scans at 140 weeks to see changes. The goal is to measure if the drug helps clear the protein deposits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic Main Campus

    Cleveland, Ohio, 44195, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Hospital Universitario Puerta de Hierro

    Majadahonda, 28222, Spain

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

Conditions

Explore the condition pages connected to this study.

TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)